NICE recommends vutrisiran for adults with ATTR-CM in final draft guidance - PharmaTimes First long-acting therapy with three-monthly dosing to target root cause of cardiac disease

#AlnylamUK #NICE #vutrisiran #Amvuttra #ATTRCM #NICEfinaldraftguidance #transthyretinamyloidosiswithcardiomyopathy #hereditaryATTR #stage1polyneuropathy #stage2polyneuropathy #NICEfinalguidance #HELIOSBstudy #cardiovascular #stiffheartdisease #AnnaTomlinson #CardiomyopathyUK
zurl.co/0yB9A